Literature DB >> 25925940

Potentially inappropriate prescribing of renally cleared drugs in elderly patients in community and aged care settings.

Aarati Khanal1, Gregory M Peterson, Ronald L Castelino, Matthew D Jose.   

Abstract

BACKGROUND: Limited data are available on the prevalence of inappropriate prescribing of renally cleared drugs in elderly patients in Australia.
OBJECTIVES: To quantify and compare the extent of inappropriate prescribing (defined as at least one drug prescribed in an excessive dose or when contraindicated with respect to renal function) of renally cleared drugs in elderly patients across the community and aged care settings, and to determine factors associated with patients being prescribed one or more potentially inappropriate renally cleared drugs.
METHODS: This retrospective study examined de-identified Home Medicines Review (HMR) and Residential Medication Management Review (RMMR) cases pertaining to 30,898 patients aged 65 years and over. Only 25 % (n = 7625) of these patients had documented information on their renal function. Among them, 4035 patients were prescribed at least one of the 31 renally cleared drugs examined in this study. For these patients, details including demographics, medications, medical conditions and pathology test results were extracted. Creatinine clearance was estimated using the Cockcroft-Gault formula, and the prevalence of inappropriate prescribing of the 31 drugs was examined on the basis of conformity with the recommendations in the Australian Medicines Handbook. Multivariate logistic regression was performed to determine the factors associated with patients being prescribed one or more potentially inappropriate renally cleared drugs.
RESULTS: The mean (± standard deviation) ages of the HMR patients (n = 3315; 59 % female) and RMMR patients (n = 720; 68 % female) were 78.3 ± 7.2 and 86 ± 7.3 years, respectively. Over one quarter of the patients (n = 1135 out of 4035; 28.1 %) prescribed the renally cleared drugs examined in this study had evidence of inappropriate prescribing of at least one of the drugs, with respect to their renal function. The drugs/drug classes most commonly prescribed inappropriately were perindopril, fenofibrate, glibenclamide, gliptins, metformin, olmesartan, bisphosphonates and strontium. The factors independently associated with patients being prescribed one or more potentially inappropriate renally cleared drugs were advancing age [odds ratio (OR) 1.06 per year increase, 95 % confidence interval (CI) 1.05-1.07; P < 0.001], the total number of renally cleared drugs prescribed (OR 1.44 per unit increase, 95 % CI 1.29-1.61; P < 0.001), presence of diabetes (OR 1.51, 95 % CI 1.30-1.76; P < 0.001), presence of heart failure (OR 1.38, 95 % CI 1.13-1.69; P < 0.005) and living in aged care facilities (OR 1.28, 95 % CI 1.06-1.5; P < 0.05).
CONCLUSION: Inappropriate prescribing of renally cleared drugs is common in older Australians. Intervention studies to improve prescribing of renally cleared drugs in the elderly appear to be warranted.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25925940     DOI: 10.1007/s40266-015-0261-1

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  63 in total

1.  Assessment of adherence to renal dosing guidelines in long-term care facilities.

Authors:  A Papaioannou; J A Clarke; G Campbell; M Bédard
Journal:  J Am Geriatr Soc       Date:  2000-11       Impact factor: 5.562

2.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

3.  A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin.

Authors:  Azim S Gangji; Tali Cukierman; Hertzel C Gerstein; Charles H Goldsmith; Catherine M Clase
Journal:  Diabetes Care       Date:  2007-02       Impact factor: 19.112

4.  Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

Authors:  Peter Jacobsen; Steen Andersen; Kasper Rossing; Berit R Jensen; Hans-Henrik Parving
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

5.  Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial.

Authors:  Sophie A Jamal; Douglas C Bauer; Kristine E Ensrud; Jane A Cauley; Marc Hochberg; Areef Ishani; Steven R Cummings
Journal:  J Bone Miner Res       Date:  2007-04       Impact factor: 6.741

Review 6.  Renal safety in patients treated with bisphosphonates for osteoporosis: a review.

Authors:  Paul D Miller; Sophie A Jamal; Pieter Evenepoel; Richard Eastell; Steven Boonen
Journal:  J Bone Miner Res       Date:  2013-10       Impact factor: 6.741

7.  Potentially inappropriate prescribing of primarily renally cleared medications for older veterans affairs nursing home patients.

Authors:  Joseph T Hanlon; Xiaoqiang Wang; Steven M Handler; Steven Weisbord; Mary Jo Pugh; Todd Semla; Roslyn A Stone; Sherrie L Aspinall
Journal:  J Am Med Dir Assoc       Date:  2010-10-02       Impact factor: 4.669

8.  Individual sulfonylureas and serious hypoglycemia in older people.

Authors:  R I Shorr; W A Ray; J R Daugherty; M R Griffin
Journal:  J Am Geriatr Soc       Date:  1996-07       Impact factor: 5.562

9.  An analysis of discharge drug prescribing amongst elderly patients with renal impairment.

Authors:  N A Wong; H W Jones
Journal:  Postgrad Med J       Date:  1998-07       Impact factor: 2.401

10.  Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: revised recommendations.

Authors:  Timothy H Mathew; David W Johnson; Graham R D Jones
Journal:  Med J Aust       Date:  2007-10-15       Impact factor: 7.738

View more
  8 in total

1.  Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort.

Authors:  Solène M Laville; Marie Metzger; Bénédicte Stengel; Christian Jacquelinet; Christian Combe; Denis Fouque; Maurice Laville; Luc Frimat; Carole Ayav; Elodie Speyer; Bruce M Robinson; Ziad A Massy; Sophie Liabeuf
Journal:  Br J Clin Pharmacol       Date:  2018-09-24       Impact factor: 4.335

2.  Application of prescribing recommendations in older people with reduced kidney function: a cross-sectional study in general practice.

Authors:  Su Wood; Duncan Petty; Liz Glidewell; Dk Theo Raynor
Journal:  Br J Gen Pract       Date:  2018-04-23       Impact factor: 5.386

3.  Inappropriate Prescription and Renal Function Among Older Patients with Cognitive Impairment.

Authors:  Eva Sönnerstam; Maria Sjölander; Maria Gustafsson
Journal:  Drugs Aging       Date:  2016-12       Impact factor: 3.923

4.  Characterisation of Drug-Related Problems and Associated Factors at a Clinical Pharmacist Service-Naïve Hospital in Northern Sweden.

Authors:  Cecilia Peterson; Maria Gustafsson
Journal:  Drugs Real World Outcomes       Date:  2017-06

5.  Drug-related problems and medication reviews among old people with dementia.

Authors:  Bettina Pfister; Jeanette Jonsson; Maria Gustafsson
Journal:  BMC Pharmacol Toxicol       Date:  2017-06-27       Impact factor: 2.483

6.  Kidney function and nephrotoxic drug use among older home-dwelling persons with or without diabetes in Finland.

Authors:  Marjo Heinjoki; Merja Karjalainen; Juha Saltevo; Miia Tiihonen; Maija Haanpää; Hannu Kautiainen; Pekka Mäntyselkä
Journal:  BMC Nephrol       Date:  2020-01-10       Impact factor: 2.388

7.  Pattern and Predictors of Medication Dosing Errors in Chronic Kidney Disease Patients in Pakistan: A Single Center Retrospective Analysis.

Authors:  Ahsan Saleem; Imran Masood
Journal:  PLoS One       Date:  2016-07-01       Impact factor: 3.240

8.  Medication-related problems in older people in Catalonia: A real-world data study.

Authors:  Amelia Troncoso-Mariño; Tomás López-Jiménez; Albert Roso-Llorach; Noemí Villén; Ester Amado-Guirado; Marina Guisado-Clavero; Sergio Fernández-Bertolin; Mariona Pons Vigues; Quintí Foguet-Boreu; Concepción Violán
Journal:  Pharmacoepidemiol Drug Saf       Date:  2020-11-26       Impact factor: 2.890

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.